| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Codeletion of chromosomes 1p and 19q is predictive for favorable prognosis in the patients with oligodendroglial tumors. We suggested that gliomas with 1p19q codeletion with some or more “astrocytic” features also had comparable biological and prognostic characteristics to those with oligodendroglial features (Oncotarget).
We showed that upfront chemotherapy for molecularly defined chemosensitive gliomas with the intension of second-look resection for initial incomplete resections might compare favorably with chemotherapy only, and suggested the usefulness of neoadjuvant strategy for the first time (J Neurooncol). We found that combination of surface localization and calcification strongly predicted 1p19q codeletion, and these radiological evaluation would help to segregate the candidates to be treated with neoadjuvant strategy (Neurosurg Rev).
|
